OVERVIEW

We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

LATEST NEWS

null

Clinical Studies

Marker has multiple clinical studies ongoing and planned for its multi-antigen T cell therapies. Target indications include acute myelogenous leukemia (AML), non-Hodgkin lymphoma (NHL), multiple myeloma (MM) and breast cancer.

null

Pipeline

Marker has a deep pipeline of clinical-stage programs that leverage the company’s unique multi-TAA cell therapy platform, addressing multiple hematologic malignancies and solid tumors. The company is also advancing its novel peptide vaccine in breast and ovarian cancer.

null

Technology

Marker’s unique cell therapy platform is the first to successfully target multiple tumor-associated antigens simultaneously, without the need for genetic modification of patients’ T cells. The result is a remarkably robust and durable anti-tumor immune response and a manufacturing process that is simpler and less costly than today’s TCR and CAR-T therapy.

null

Management Team

Marker is led by an executive management team specialized in cancer immunotherapy, bringing together extensive corporate, clinical, translational and medical experience. With its world-class scientific advisors, Marker is well positioned to advance its science-based approach to transforming the cell therapy landscape.